secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-065308
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella announces Phase 3 SELVA topline results for QTORIN in lymphatic malformations; specifics not in filing excerpt
--------------------------------------------------------------------------------

- Topline data from Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations announced on Feb 24, 2026.
- Investor conference call held at 8:00 a.m. ET; presentation slides furnished as Exhibit 99.1.
- Exact efficacy and safety endpoints not disclosed in this filing excerpt; full results expected in the presentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/0001193125-26-065308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/pvla-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-065308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer